CRISPR News
@crispr-news.bsky.social
The latest CRISPR breakthroughs
To the incredible CRISPR community: Wishing you and your loved ones a joyful Christmas and a groundbreaking New Year! Here's to 2025 bringing even more transformative breakthroughs.
December 24, 2024 at 10:33 AM
To the incredible CRISPR community: Wishing you and your loved ones a joyful Christmas and a groundbreaking New Year! Here's to 2025 bringing even more transformative breakthroughs.
CRISPR history part 24/24: December 2023: The FDA approved the first CRISPR-based therapy for sickle cell disease, CASGEVY™ (exagamglogene autotemcel) developed by Vertex Pharmaceuticals in collaboration with CRISPR Therapeutics.
December 23, 2024 at 9:50 AM
CRISPR history part 24/24: December 2023: The FDA approved the first CRISPR-based therapy for sickle cell disease, CASGEVY™ (exagamglogene autotemcel) developed by Vertex Pharmaceuticals in collaboration with CRISPR Therapeutics.
CRISPR history part 23/24: 2022: He is released from prison.
December 23, 2024 at 9:50 AM
CRISPR history part 23/24: 2022: He is released from prison.
CRISPR history part 22/24: 2020: Nobel prize awared to Emmanuelle Charpentier and Jennifer Doudna. They were recognized for their development of the CRISPR-Cas9 gene-editing tool.
December 23, 2024 at 9:50 AM
CRISPR history part 22/24: 2020: Nobel prize awared to Emmanuelle Charpentier and Jennifer Doudna. They were recognized for their development of the CRISPR-Cas9 gene-editing tool.
CRISPR history part 21/24: March 2020: Editas Medicine performs the first in vivo clinical study using CRISPR-Cas9 for inherited blindness by injecting EDIT-101 into the retina.
December 23, 2024 at 9:50 AM
CRISPR history part 21/24: March 2020: Editas Medicine performs the first in vivo clinical study using CRISPR-Cas9 for inherited blindness by injecting EDIT-101 into the retina.
CRISPR history part 20/24: July 2019: First ex vivo gene therapy using CRISPR-Cas9 performed in the US on patient with sickle cell anemia.
December 23, 2024 at 9:50 AM
CRISPR history part 20/24: July 2019: First ex vivo gene therapy using CRISPR-Cas9 performed in the US on patient with sickle cell anemia.
CRISPR history part 19/24: November 2018: Jiankui He announces the birth of the first gene-edited babies (Lulu and Nana) in China, created using CRISPR-Cas9, sparking widespread ethical concerns and condemnation.
December 23, 2024 at 9:50 AM
CRISPR history part 19/24: November 2018: Jiankui He announces the birth of the first gene-edited babies (Lulu and Nana) in China, created using CRISPR-Cas9, sparking widespread ethical concerns and condemnation.
CRISPR history part 18/24: July 2017: First in vivo clinical study using ZFN technology to perform in situ genomic editing for Hunter Syndrome is performed.
December 23, 2024 at 9:50 AM
CRISPR history part 18/24: July 2017: First in vivo clinical study using ZFN technology to perform in situ genomic editing for Hunter Syndrome is performed.
CRISPR history part 17/24: 2016: First clinical study of CRISPR-Cas9 commenced in China, with PD-1 gene inactivated in blood cells for lung cancer therapy.
December 23, 2024 at 9:50 AM
CRISPR history part 17/24: 2016: First clinical study of CRISPR-Cas9 commenced in China, with PD-1 gene inactivated in blood cells for lung cancer therapy.
CRISPR history part 16/24: April 2015: Liang et al. (China) publish the first paper on using CRISPR-Cas9 on human embryonic cells. The researchers used non-viable embryos and emphasized the limitations and inefficiencies of the technique at the time.
December 23, 2024 at 9:50 AM
CRISPR history part 16/24: April 2015: Liang et al. (China) publish the first paper on using CRISPR-Cas9 on human embryonic cells. The researchers used non-viable embryos and emphasized the limitations and inefficiencies of the technique at the time.
CRISPR history part 15/24: March 2015: A report from the Napa conference discourages heritable changes in human embryos. Also, a commentary in Nature warns against the risks of editing the human germline.
December 23, 2024 at 9:50 AM
CRISPR history part 15/24: March 2015: A report from the Napa conference discourages heritable changes in human embryos. Also, a commentary in Nature warns against the risks of editing the human germline.
CRISPR history part 14/24: January 2015: Doudna organizes a conference in Napa Valley on the ethical implications of genomic modification.
December 23, 2024 at 9:50 AM
CRISPR history part 14/24: January 2015: Doudna organizes a conference in Napa Valley on the ethical implications of genomic modification.
CRISPR history part 13/24: 2014+: Patent disputes between Doudna/Charpentier & Zhang/Broad Institute. In Feb 2022, the US Patent & TM Office Appeal Board confirms the priority of Zhang & the Broad Institute. Doudna & Charpentier win a similar patent disputes in other countries.
December 23, 2024 at 9:50 AM
CRISPR history part 13/24: 2014+: Patent disputes between Doudna/Charpentier & Zhang/Broad Institute. In Feb 2022, the US Patent & TM Office Appeal Board confirms the priority of Zhang & the Broad Institute. Doudna & Charpentier win a similar patent disputes in other countries.
CRISPR history part 12/24: April 2014: Zhang's patent is approved in the US, while Doudna's patent application remains pending.
December 23, 2024 at 9:50 AM
CRISPR history part 12/24: April 2014: Zhang's patent is approved in the US, while Doudna's patent application remains pending.
CRISPR history part 11/24: Early 2013: Multiple groups, including those led by Church, Zhang, Doudna, Kim, and Joung, report the successful use of CRISPR-Cas9 for genome editing in eukaryotic cells. Joung's team demonstrates use on germline cells for the first time (zebrafish).
December 23, 2024 at 9:50 AM
CRISPR history part 11/24: Early 2013: Multiple groups, including those led by Church, Zhang, Doudna, Kim, and Joung, report the successful use of CRISPR-Cas9 for genome editing in eukaryotic cells. Joung's team demonstrates use on germline cells for the first time (zebrafish).
CRISPR history part 10/24: Late 2012: Zhang and the Broad Institute submit a patent application in December, simultaneously with their paper on human cell editing being accepted by Science.
December 23, 2024 at 9:50 AM
CRISPR history part 10/24: Late 2012: Zhang and the Broad Institute submit a patent application in December, simultaneously with their paper on human cell editing being accepted by Science.
CRISPR history part 9/24: 2012: Jinek et al. show that crRNA and tracrRNA can be combined into a single guide RNA (sgRNA) and that this is functional, enabling the complete CRISPR-Cas9 system to be assembled in vitro and shown to cut DNA in a controlled fashion.
December 23, 2024 at 9:50 AM
CRISPR history part 9/24: 2012: Jinek et al. show that crRNA and tracrRNA can be combined into a single guide RNA (sgRNA) and that this is functional, enabling the complete CRISPR-Cas9 system to be assembled in vitro and shown to cut DNA in a controlled fashion.
CRISPR history part 8/24: 2011: Charpentier's group discovers tracrRNA (trans-activating CRISPR RNA) which is crucial for crRNA processing and nuclease activity.
December 23, 2024 at 9:50 AM
CRISPR history part 8/24: 2011: Charpentier's group discovers tracrRNA (trans-activating CRISPR RNA) which is crucial for crRNA processing and nuclease activity.
CRISPR history part 7/24: 2009: Mojica et al. describe the protospacer adjacent motifs (PAMs) which signal foreign DNA.
December 23, 2024 at 9:50 AM
CRISPR history part 7/24: 2009: Mojica et al. describe the protospacer adjacent motifs (PAMs) which signal foreign DNA.
CRISPR history part 6/24: 2008: Marraffini and Sontheimer demonstrate that the CRISPR system targets foreign DNA and not mRNA. Brouns et al. describe crRNA (CRISPR-associated RNA) which are produced from the CRISPR locus.
December 23, 2024 at 9:50 AM
CRISPR history part 6/24: 2008: Marraffini and Sontheimer demonstrate that the CRISPR system targets foreign DNA and not mRNA. Brouns et al. describe crRNA (CRISPR-associated RNA) which are produced from the CRISPR locus.
CRISPR history part 5/24: 2007: Barrangou & Horvath, working with Streptococcus thermophilus, discover that bacteria acquire CRISPR spacers when attacked by viruses, leading to immunity. They obtain a patent, and Danisco uses CRISPR technology to "vaccinate" bacterial cultures.
December 23, 2024 at 9:50 AM
CRISPR history part 5/24: 2007: Barrangou & Horvath, working with Streptococcus thermophilus, discover that bacteria acquire CRISPR spacers when attacked by viruses, leading to immunity. They obtain a patent, and Danisco uses CRISPR technology to "vaccinate" bacterial cultures.
CRISPR history part 4/24: 2005: Mojica hypothesizes that CRISPR loci contain fragments of foreign DNA and are part of a prokaryotic immune system. Bolotin et al. also find that CRISPR spacers are of extrachromosomal origin. Pourcel et al. reach a similar conclusion.
December 23, 2024 at 9:50 AM
CRISPR history part 4/24: 2005: Mojica hypothesizes that CRISPR loci contain fragments of foreign DNA and are part of a prokaryotic immune system. Bolotin et al. also find that CRISPR spacers are of extrachromosomal origin. Pourcel et al. reach a similar conclusion.
CRISPR history part 3/24: 2002: Jansen et al. propose the acronym CRISPR and identify genes (cas genes) associated with the repeats. Independently, Koonin's team described the same neighborhood of genes, but did not associate them with CRISPR arrays.
December 23, 2024 at 9:50 AM
CRISPR history part 3/24: 2002: Jansen et al. propose the acronym CRISPR and identify genes (cas genes) associated with the repeats. Independently, Koonin's team described the same neighborhood of genes, but did not associate them with CRISPR arrays.
CRISPR history part 2/24: 1993: Mojica identifies similar repeat structures in the archaeal genome of Haloferax mediterranei, suggesting an important functional role for these elements.
December 23, 2024 at 9:50 AM
CRISPR history part 2/24: 1993: Mojica identifies similar repeat structures in the archaeal genome of Haloferax mediterranei, suggesting an important functional role for these elements.
CRISPR history part 1/24: 1987: Short, unusual DNA repeats are observed in Escherichia coli bacteria by Ishino et al. in Japan. These are later named CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), but their function is unknown at this point.
December 23, 2024 at 9:50 AM
CRISPR history part 1/24: 1987: Short, unusual DNA repeats are observed in Escherichia coli bacteria by Ishino et al. in Japan. These are later named CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), but their function is unknown at this point.